E7389

Phase 1Completed

1 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Cancer

Conditions

Cancer

Trial Timeline

Jun 1, 2006 → Feb 1, 2008

NCT ID

NCT00326950

About E7389

E7389 is a phase 1 stage product being developed by Eisai for Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00326950. Target conditions include Cancer.

What happened to similar drugs?

20 of 20 similar drugs in Cancer were approved

Approved (20) Terminated (4) Active (0)

✅arzoxifeneEli LillyApproved

✅EnzalutamideAstellas PharmaApproved

✅Enzalutamide + Androgen deprivation therapy (ADT)Astellas PharmaApproved

✅Enzalutamide + Abiraterone + Placebo for Enzalutamide + PrednisoneAstellas PharmaApproved

✅EnzalutamideAstellas PharmaApproved

✅Enzalutamide + FlutamideAstellas PharmaApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (8)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01432886	Phase 1	Completed	Oct 1, 2011	Dec 1, 2013	Breast Cancer
NCT00413192	Phase 2	Completed	Jan 1, 2007	Feb 1, 2013	Soft Tissue Sarcoma
NCT00326950	Phase 1	Completed	Jun 1, 2006	Feb 1, 2008	Cancer
NCT00278993	Phase 2	Completed	Jan 1, 2006	Jan 1, 2008	Prostate Cancer
NCT00246090	Phase 2	Completed	Oct 1, 2005	Sep 1, 2007	Breast Cancer
NCT00097721	Phase 2	Completed	Sep 1, 2004	Nov 1, 2006	Breast Neoplasms
NCT00069264	Phase 1	Completed	Sep 1, 2003	Jul 1, 2005	Advanced Solid Tumors
NCT00069277	Phase 1	Completed	Aug 1, 2003	Apr 1, 2005	Cancer

Competing Products

20 competing products in Cancer

See all competitors

Product	Company	Stage	Hype Score
mFOLFOX regimen + Mitazalimab	Alligator Bioscience AB	Phase 2/3	35
Intratumoral Mitazalimab + Intratumoral Nivolumab	Alligator Bioscience AB	Phase 1	26
mRNA-2416	Moderna	Phase 2	0
Doxorubicin Hydrochloride Liposome Injection	Dr. Reddy's Laboratories	Phase 1	26
Veliparib	AbbVie	Phase 2	27
AK-105	Akeso	Phase 1	29
XL820	Exelixis	Phase 1	26
Lymphoseek	Navidea Biopharmaceuticals	Phase 3	30
Lymphoseek	Navidea Biopharmaceuticals	Phase 3	30
ALT-P7 (HM2-MMAE)	Alteogen	Phase 1	29
pegylated liposomal doxorubicin (PLD) + PD-1	CSPC Pharmaceutical Group Limited	Phase 2	31
Biomarkers blood, urine and microbiota samples	Eli Lilly	Pre-clinical	30
gemcitabine + paclitaxel + bevacizumab	Eli Lilly	Phase 2	35
pemetrexed	Eli Lilly	Phase 2	27
LY3300054 + Prexasertib	Eli Lilly	Phase 1	29
BBP-398 with nivolumab	BridgeBio Pharma	Phase 1	18
Cetuximab + Oxaliplatin + Capecitabine	Eli Lilly	Phase 2	35
Necitumumab + Gemcitabine + Carboplatin	Eli Lilly	Phase 2	27
Gemcitabine + Adriamycine + Paclitaxel	Eli Lilly	Phase 2	35
Selpercatinib	Eli Lilly	Pre-clinical	26